Tom Snow, General Manager at US Oncology, Sanofi, shared a post on LinkedIn:
“Today, the FDA accepted for Priority Review Sanofi’s application for our investigational combination regimen in newly diagnosed Multiple Myeloma. This important milestone highlights a key step towards potentially addressing the unmet needs of people living with this blood cancer. Read on to learn more here.”
Source: Tom Snow/LinkedIn